Adaptive Biotechnologies Corp (ADPT)vsMerck & Company Inc (MRK)
ADPT
Adaptive Biotechnologies Corp
$13.53
-3.63%
HEALTHCARE · Cap: $2.16B
MRK
Merck & Company Inc
$110.95
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 23372% more annual revenue ($65.01B vs $276.98M). MRK leads profitability with a 28.1% profit margin vs -21.5%. MRK earns a higher WallStSmart Score of 59/100 (C).
ADPT
Avoid32
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+52.2%
Fair Value
$32.68
Current Price
$13.53
$19.15 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$110.95
$14.47 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 51.0% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Trading at 9.5x book value
0.0% earnings growth
Elevated debt levels
ROE of -27.8% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 51.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : ADPT
The primary concerns for ADPT are Price/Book, EPS Growth, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ADPT profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.30 — expect wider price swings.
ADPT is growing revenue faster at 51.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 32/100), backed by strong 28.1% margins. ADPT offers better value entry with a 52.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?